cetuximab + Mitoxantrone
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Androgen-independent Prostate Cancer
Conditions
Androgen-independent Prostate Cancer
Trial Timeline
May 1, 2008 → Jun 1, 2011
NCT ID
NCT00661492About cetuximab + Mitoxantrone
cetuximab + Mitoxantrone is a phase 2 stage product being developed by Eli Lilly for Androgen-independent Prostate Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00661492. Target conditions include Androgen-independent Prostate Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00661492 | Phase 2 | Completed |
Competing Products
1 competing product in Androgen-independent Prostate Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| lorigerlimab + docetaxel + Prednisone | MacroGenics | Phase 2 | 44 |